Abstract Drugs interact with their targets in different ways. A diversity of modeling approaches exists to describe the combination effects of two drugs. We investigate several combination effect terms (CET) regarding their underlying mechanism based on drug-receptor binding kinetics, empirical and statistical summation principles and indirect response models. A list with properties is provided and the interrelationship of the CETs is analyzed. A method is presented to calculate the optimal drug concentration pair to produce the half-maximal combination effect. This work provides a comprehensive overview of typically applied CETs and should shed light into the question as to which CET is appropriate for application in pharmacokinetic/pharmacodynamic models to describe a specific drug-drug interaction mechanism.
Introduction
Drugs interact with their targets in many different ways, e.g. compete for the same receptor, aim on different targets or act as antagonists to name a few. Understanding interactions is crucial to develop beneficial combination therapies but also to decode undesired effects. A wide range of diverse methodologies were developed to describe different drug-drug interaction (DDI) mechanisms. This work investigates and summarizes typically applied DDI mechanisms in pharmacokinetic/pharmacodynamic (PKPD) modeling [1] .
In PKPD modeling the effect of a single dose is usually described by the Hill equation [2] [3] [4] , also called sigmoidal function or Emax model. The Hill equation can be derived from first principles of drug-receptor binding kinetics [5] and describes a non-linear profile with saturation behavior. The equation has simple characteristics such as a maximal effect parameter to denote the saturation, a parameter to describe the concentration producing the half-maximal effect, and a coefficient to alter the shape towards sigmoidal profiles.
The effects of two drugs administered in combination depend on the interaction mechanism of the drugs. Ariëns and colleagues [6] [7] [8] presented mathematical expressions related to the Hill equation to describe different DDI mechanisms where we will focus on competitive, uncompetitive and non-competitive interaction. Other commonly used combination effect terms (CETs) are based on statistical assumptions such as Bliss Independence [9, 10] , Loewe Additivity as in Greco's model [9] , simple summation of Hill equations, indirect response models [10] , generalized surface response models [11] [12] [13] and sometimes equipped with additional interaction parameters [14, 15] .
Although many of these CETs are extensively presented in the literature, a clear derivation of the CETs is often missing and therefore the underlying interaction mechanism is not obvious.
In this manuscript, we focus on CETs derived from drug-receptor binding kinetics, empirical or statistical summation principles, and interactions received from an indirect response model. We reveal the underlying mechanisms, rigorously derive the CETs, and investigate their properties. Some CETs are compared regarding the intensity of their predicted effects. Finally, we provide for selected CETs the optimal minimal drug concentration pair necessary to achieve the half-maximal effect.
In general, CETs are subunits which can be incorporated at any level of the full model complexity, e.g. in semimechanism based PKPD models, in more mechanistic approaches such as cell cycle based models or even in quantitative systems pharmacology models. To build a realistic model, CETs have to be chosen accordingly to the underlying interaction mechanism and positioned in the right spot of the interaction. Altogether this work should shed light into the question as to which CET is appropriate for application to describe a specific drug-drug interaction mechanism.
Derivation and properties of combination effect terms for drug-drug interaction
Introduction to combination effect terms 
with the restriction I max 1.
Pharmacokinetic/pharmacodynamic drug-drug interaction modeling situations
In PKPD modeling roughly two categories of models are applied to describe data from drug-drug interaction (DDI) experiments. Data measured at two time points, i.e. at start and end of the experiment, are typically modeled by an effect surface without a time dimension of the form
where P 0 is the response, e.g. proliferating cells, if no drug is present, and P the response after drug administration; see [14] or [16] for more details. The inhibition mechanism of the two drugs is specified by the CET IðC A ; C B Þ. From Eq. (4) restriction I C A ; C B ð Þ 1 is obvious. For models characterizing dynamic growth over time, first a growth function g [17, 18] needs to be specified. Then cytostatic DDI effects can be modeled by inhibition of growth
and cytotoxic effects by a killing term
where the CET is E C A ; C B ð Þ. In the above models, C A and C B can be the drug concentration in plasma [15] or delayed concentration effects [19] , e.g. due to signaling pathways. A general PKPD structure with cytotoxic drug effects is shown in Fig. 1 , to visualize a typical spot of DDI. Modified or extended formulations of this structure are frequently applied in drug development, see e.g. [15, [19] [20] [21] [22] [23] [24] [25] [26] . Moreover, also in more mechanism-based models, such as cell cycle models [27, 28] , appropriate CETs are necessary to model DDI at Fig. 1 A schematic of a typical semi-mechanistic PKPD model with possible delayed drug effects and apoptotic cell population. The interaction of the two drugs is indicated by E denoting an appropriate combination effect term specific interaction targets, e.g. on different cell phases or induction of apoptosis [26] . The major task when developing a DDI model of the above forms is to incorporate an appropriate CET at a specific spot in the PKPD model that describes the underlying DDI mechanism.
Combination effect terms
In general, a CET is a mathematical function that combines the single drug concentrations C A and C B together with their individual parameters ðE maxA ; EC 50A ; c A Þ and ðE maxB ; EC 50B ; c B Þ. More precisely, the parameters of a CET are those from the individual drugs and the maximal combination effect E maxAB of the CET is then a result from the specific structure of the CET. We call a CET symmetric if interchanging the roles of drugs A and B leads to the same CET. Let us state and formalize the desirable properties of CETs that one somehow implicitly takes for granted:
Positivity:
The effect of a CET should be bounded from above and below:
Scaling: The CET should be linear in the maximal single effects, i.e. a doubling of E max or E maxA and E maxB simultaneously should result in a doubling of the CET effect.
Diagonality: Symmetric CETs applied to drugs A and B with similar properties and c A ¼ c B ¼ 1, should be describable as a single effect term, i.e.
where r is a CET-specific constant. Hence, a symmetric CET acts like a single effect term with the double concentration plus perhaps some quadratic deviation. In this work, CETs are derived from three structurally different underlying mechanism categories:
(1) Drug-receptor binding kinetics (2) Empirical and statistical summation principles (3) Interactions from an indirect response model
CETs based on drug-receptor binding kinetics
Ariëns and colleagues [6] presented the competitive, uncompetitive and non-competitive CETs but, to our knowledge, omitted the derivations in their publications. In this section we deduce these three CETs from drug-receptor binding kinetics. The construction consists of two components: (i) establishing the underlying drug-receptor binding system, and (ii) defining the effect based on the drug-receptor complexes.
A general drug-receptor binding system is based on the following mechanisms. Molecules C A of drug A bind to a receptor R and produce a drug-receptor complex RC A . Drug molecules C B of drug B also bind to this receptor R producing a drug-receptor complex RC B and additionally bind to RC A resulting in a third complex RC AB : A necessary assumption for Ariëns CETs is that the binding and dissociation rates of drug B to produce RC A or RC AB are equal. The ordinary differential equations [29] are:
The binding rates are k onA and k onB , and the dissociation rates are k offA and k offB . The total amount of receptors
and therefore a constant number of total receptors R 0 tot exists. For drugs following target-mediated drug disposition the total receptor is additionally modulated. The resulting CETs due to Ariëns can be compared with TMDD models in baseline (see Eq. (21) in [30] for the competitive CET). Typically, rapid binding of the drug with the receptor is assumed to produce the complex, see originally [5, 29] . From this assumption, k onX and k offX , where X stands for A or B, can be replaced by their dissociation constant
. Under such steady state assumptions and observing that the total concentration of receptors R 0 tot is constant, the equation system for the complexes RC A ; RC B and RC AB is 1 þ
This equation system (12) can be adjusted depending on which complexes are involved in the specific drug combination mechanism. The resulting equation system can then be solved with respect to the complexes. In the second step, the CETs are constructed by summation of the complexes driving the combination effects. For this purpose the intrinsic activity (the ability of a complex to produce maximum functional response) is applied. Let a and b denote the intrinsic activities of drugs A and B varying from 0 to 1 when acting as single drug. We define the functions 
Hence, the complexes RC A and RC B are either included or not depending on their contribution to the total effect. The function f a; b ð Þ!0 combines the intrinsic activities a and b and describes how the interaction of the intrinsic activities of drug A and B drive the contribution of the complex RC AB to the total effect. Ariëns presented the summation rules for the competitive, uncompetitive and non-competitive mechanisms. Using the solution of complexes RC A , RC B and RC AB from Eq. (12), Eq. (13) can be reformulated to the general form of a CET
See Appendix 1. From Eq. (14) it can be directly seen that any CET based on drug receptor binding kinetics can be written with dimensionless variables Based on Eq. (14) we obtain the Emax-formulation EðC A ; C B Þ for appropriate assignment of the total receptors R 0 tot and the intrinsic activities. Further system (5)- (10) ensures that the effect E AB is never negative and bounded by a maximal effect E maxAB , i.e. E maxAB ! E AB ! 0 for C A ; C B ! 0. For the inhibitory formulation I C A ; C B ð Þ we have a; b; f a; b ð Þ 1 and, thus, I maxAB 1.
Competitive CET
For a competitive interaction, two drugs A and B exhibit an affinity for the same receptor system R [6] . More precisely, if a receptor is occupied by molecules of drug A, then molecules of drug B cannot bind to this receptor, see Fig. 2a for the binding schematic. The complex RC AB is not present in this mechanism and equation system (12) reduces to
The two complexes RC A and RC B are added together with their intrinsic activity a; b as weights by
resulting in
See Appendix 2. With the single maximal effects E maxA ¼ aR [32] . If drug B is an antagonist, i.e. binding of drug molecules only cause a blockage of the receptors and does not produce an effect, i.e. b ¼ 0; E maxB ¼ 0 one obtains
which is also called the Gaddum equation [33] .
Uncompetitive CET
In uncompetitive interaction, drug B binds to the complex RC A . Binding of drug B to R does not occur and therefore no complex RC B exists; see Fig. 2b . Hence, drug B only produces an effect if drug A forms the complex RC A . If drug B is administered alone no effect occurs, whereas if drug A is given alone, the effect corresponds to the single case. This is a non-symmetric behavior. The equation system for the complexes is
and the summation of the complexes [6] becomes
where À1 b 
We then obtain the E max formulation
Since b 0
and not E maxB is present in Eq. (22), the actual value of b 0 has to be determined from the combination data and describes a synergistic or antagonistic influence on the combination effect. The maximal combination effect is
For b 0 0 a reasonable inhibitory formulation exists.
Non-competitive CET
The non-competitive situation corresponds to the general scenario represented by Eqs. (5)- (10) where all complexes are involved see Fig. 2c for schematic. According to Ariëns [6] the complex RC B does not contribute to the effect and the summation reads
Note the appearance of
in the denominator of Eq. (23) 
in contrast to Eq. (21). The Emax-formulation reads
In ''Discussion'' section we additionally discuss a noncompetitive term from [14] .
CETs from empirical and statistical summation principles
In this section, CETs are considered that are derived under an additivity or no-interaction assumption. However, we emphasize that the term ''additivity'' is used to describe different approaches [34] [35] [36] [37] , and therefore we cover all the different additivities as summation principles in the following.
Loewe Additivity CET
Loewe Additivity [34, 38] assumes that two drugs act additively through a similar mechanism on the same target [39, 40] , see Fig. 2d . Given the single drug EC 50 's , the concentrations C A and C B necessary to produce the halfmaximal combination effect have to fulfill
Extending Eq. (25) for an arbitrary effect E ranging from 0 to E maxAB gives
where DC X is the concentration that produces for the single drug the given effect E and X either represents A or B.
Greco and colleagues [9] applied the single drug Hill Eq. (1) of the form
and rearranged Eq. (27) with respect to DC X . Then substituting in Eq. (26) gives
See Appendix 4. For c A ¼ c B ¼ c, Eq. (28) can be solved explicitly with respect to E and we obtain the Loewe CET
See Appendix 4. In Eq. (29) 
Bliss Independence CET
Bliss Independence [41] describes the additive effect of two drugs at different targets with independent mechanisms and no interaction between the drug action exists [39] , see Fig. 2e . Bliss Independence is derived from probability theory. The probability for non-mutually exclusive events that either drug A or drug B acts is
Following Jonker et al. [42] we set the probability of a single effect based on the single Hill function Eq. (1) with E max ¼ 1 and c ¼ 1 as
where X represents either A or B. Equation (31) ranges from 0 to 1. Substituting Eq. (31) in Eq. (30) gives
We multiply Eq. (32) with E max , introduce the Hill parameters, and obtain
where a similar maximal effect of both drugs is assumed. Substituting
2 . Equation (35) corresponds to arguments from Chou and Talalay [40] for mutually nonexclusive drugs acting on different targets.
Greco's model CET
Greco et al. [9] further extended Eq. (28) by adding an additional term resulting in
See Fig. 2f . In Eq. (36) an interaction parameter a is applied to indicate antagonism (a\0Þ and synergism (a [ 0Þ. For c A ¼ c B ¼ c Eq. (36) could be solved explicitly with respect to E and Greco's CET reads
As shown before for a ¼ 0, Eq. (37) is the Loewe CET as presented in Eq. (29) . For a ¼ 1 Eq. (37) formally results in the Bliss CET with c A ¼ c B ¼ 1. But keep in mind that the Bliss CET describes the effect when the two drugs act on different targets whereas the Greco CET is based on the Loewe Additivity assuming one target.
However, allowing negativity of the interaction parameter a could lead to a negative effect. As example we set c ¼ 1, C A ¼ EC 50A and C B ¼ EC 50B . Then we have
which is negative for a from -3 to -2.
Summation CET
An empirical approach to construct a CET with an increased maximal combination effect is to simply sum up the single drug effect terms, compare [15] for a linear CET and [19] for delayed effects of non-linear CETs, and see Fig. 2g . Assuming that the drugs act at different targets the summation CET reads
In contrast to all derived CETs before, the maximal combination effect is now the sum of the single maximal effects:
It is clear from Eq. (39) , that an inhibitory formulation of the summation CET does not exist. The scaling condition is fulfilled but diagonality is violated, see Appendix 6.
CETs from indirect response models
Indirect response models (IDR) [43] are probably the most frequently applied components in PKPD and are also important parts in complex systems pharmacology models. In this Section, we derive CETs from IDR models where the drugs either act on the inhibition or the stimulation of the production rate [10] .
IDR inhibition CET
The first form is
where Res denotes a response, k in is the production rate, k out the loss rate, and iðCÞ the single drug inhibition model Eq. (3), compare Fig. 2h for schematic. Rearranging Eq. (40) gives
and the CET is obtained by calculating See Appendix 7. In [14, 16] , Eq. (42) was applied to non-dynamic models, compare Eq. (4). In the literature [10, 14, 16] , Eq. (42) was thought to be the non-competitive CET from Ariën's approach. Although Eq. (42) looks
structurally similar to the CETs from Ariën's theory, Eq. (42) does not match into the Ariëns formalism, since multiplication of the single maximal values
produces a quadratic amount of total receptors whereas the Ariëns concept implicitly assumes a fixed number R
In the Emax-formulation of Eq. (42) the effect could become negative which can simply be seen from
Hence, Eq. (42) is only useful in the inhibitory formulation Eq. (42).
IDR stimulation CET
If the production rate is stimulated in IDRs
compare Fig. 2i for schematic, then by similar calculations the corresponding CET reads
In [44] , Eq. (43) was applied in non-dynamic models describing stimulatory effects. Note that no negativity occurs because of the summation of the term E maxA E maxB in Eq. (43) . Nevertheless, justification based on Ariën's approach also does not hold, because of the quadratic amount of receptors and also the scaling property is violated. Equation (44) can be considered as an extension of the summation CET Eq. (38) with an additional build-in synergism term e C A ð Þe C B ð Þ to produce a higher maximal combination effect. In [20] a structurally similar approach to Eq. (44) with linear CETs was applied.
Summary of CET properties
Properties of the presented CETs are summarized in Table 1 . We indicate the construction principles and symmetry of CETs. Validity of the desired properties namely positivity, scaling and diagonality are stated. The maximal combination effect E maxAB is listed and we indicate whether the CET can be written in an inhibitory form, i.e. can be applied as 1 À I C A ; C B ð Þ ð Þ , compare e.g. Equation (4). In Fig. 3 , a comparison of the presented CETs with respect to the maximal effect and the number of targets is shown.
Relationship of CETs and the optimal concentration pair for half-maximal effect
We investigated several DDI mechanisms and derived the corresponding CETs. Hence, if the underlying DDI mechanism is known in application, the appropriate CET can be applied directly at the specific interaction position in the PKPD model. For example, often the combination of endogenous substances with exogenous agents acts in a competitive manner on the same receptor [30] . However, if the underlying DDI mechanism is not known, e.g. in early drug development, different CETs have to be tested and selection criteria need to be formulated. 
First, we present relationships of the symmetric CETs regarding their effect, if the same drug concentration is applied, which may help to identify the corresponding DDI mechanism. Second, we investigate selected CETs regarding the optimal drug concentration pair to achieve the half-maximal effect. In contrast to the single case, where a unique concentration, the EC 50 , exists to produce the half-maximal effect, for CETs several concentration combinations are possible for the half-maximal combination effect E maxAB 2 . Based on a pharmacological reasonable objective function, we determine the optimal concentration pair for each CET and classify the interaction of the two drugs into synergistic, additive and antagonistic.
Relationship and ranking of the symmetric CETs
A ranking of the presented symmetric CETs is established with respect to their effect for the same drug concentrations. In the case of arbitrary E maxA ; E maxB ; c A ; c B [ 0 one can show (Appendix 8)
For E maxA ¼ E maxB and c A ; c B [ 0 we obtain Fig. 4 .
Optimal concentration pair for the half-maximal effect of CETs
For CETs the discussion about the necessary concentrations to produce the half-maximal combination effect form a curve in the 2-dimensional ðC A ; C B Þ-space that we call the half-maximal effect curve.
To calculate the optimal concentration pair for a CET, two steps are necessary: (i) establish the half-maximal effect curve, and (ii) optimize the concentration pair with respect to an appropriate objective function.
Any presented CET in this work could be written with the dimensionless variables, i.e. as a fraction of actual (18), (22), (24), (29), (33), (37) , (39) , (42) and (43) . For simplicity we assume c A ¼ c B ¼ 1 in this Section. The half-maximal effect curve of all possible concentration pairs ðC A ; C B Þ for the given single EC 50A and EC 50B reads
where u is a function being specific for the underlying CET. 
If it is assumed that the two drugs do not share the same target, do not interfere with each other, and are mutually non-exclusive the resulting combination index is
See [40] . However, both approaches Eqs. (49) 
See Fig. 5b 
and again all pairs on the half-maximal effect curve are optimal, see Fig. 5c .
Comparing Eq. (25) More care is necessary for CETs with higher maximal combination effects than the maximal effect from the single drug, since the objective functions Eqs. (49), (50) defining the classifications have to be scaled appropriately with E maxA and E maxB . For the summation CET Eq. (39) application of our minimization method leads to the optimal solution
For more general assumptions, such as different maximal single effects and individual Hill coefficients, the presented method in the Appendix can be applied but more detailed investigations and calculations are necessary.
Discussion
CETs are important components to construct PKPD models with DDI effects. Therefore, it is essential to have a rigorous knowledge about their underlying pharmacological mechanism and mathematical properties.
We investigated CETs based on drug receptor binding kinetics, statistical and empirical summation principles, and indirect response models. The presented CETs could be categorized based on different criteria. First, for some CETs the maximal combination effect E maxAB , is the maximal single effect, whereas for others it is a combination of the two single maximal effects. Second, most CETs are symmetric, i.e. interchanging the roles of A and B leads to the same CET. However, we also presented non-symmetric CETs where only an effect exists, if drug A is an agonist and drug B an antagonist. Third, some CETs describe the DDI on one target, whereas others assume action on two targets.
A general drug-receptor binding kinetic concept is presented according to Ariëns who derived the competitive, uncompetitive and non-competitive CETs from first principles. These three CETs fulfill positivity and scaling, and the symmetric competitive CET also diagonality.
Additive interaction is usually defined based on two different principles. The Loewe Additivity assumes that the two drugs act on one target whereas Bliss Independence assumes two independent mechanisms on two different targets. From these two fundamental principles we also derived CETs which describe two different types of additivity. The constructed Loewe CET becomes equal to the competitive CET, derived from drug-receptor binding kinetics, if the single maximal effects are equal and the Hill coefficients have the value 1. Further we investigated Greco's model that is based on the Loewe Additivity. This model is equipped with an interaction parameter a to account for antagonistic or synergistic behavior but surprisingly can produce negative effects, if the interaction parameter indicates antagonism and the CET is used with sufficiently large concentrations. This is not an issue when fitting data only but may produce paradox results for simulations. However, the interaction parameter a in the Greco model connects the Loewe Additivity for a ¼ 0 with the Bliss Independence for a ¼ 1, which explains the flexibility of Greco's model. All these CETs are symmetric and fulfill the diagonality condition but CETs with two targets have some deviation in contrast to CETs describing one target. The summation CET is structurally different since it realizes a maximal combination effect which is the sum of the single maximal effects and it does not fulfill the diagonality criteria.
Finally, we investigated CETs derived from indirect response models. These CETs are fundamentally different to the previous ones from Ariëns, Loewe and Bliss due to a multiplication term of the single maximal drug effects in the enumerator. They do not fulfill the scaling and diagonality conditions. However, interestingly the frequently applied CET Eq. (42) is structurally close to the Bliss CET if the two single maximal inhibition parameters are nearly unity.
For comparison of the different symmetric CETs, a ranking regarding their combination effect for the same drug concentrations was established. Depending on the relations of single maximal effect parameters among each other and the Hill coefficients, orderings of different CETs can be shown. Such relationships may open the route to identify an appropriate CET regarding its predicted effect.
The last part of this work was dedicated to the computation of an optimal concentration pair, which is essential in application. In general, optimization can be performed at different levels of the model. For example, Gabrielsson et al. [46] presented the optimal concentration pair for a cytotoxic and a cytostatic drug to achieve tumor stasis for a specific tumor growth PKPD model. Since we are interested in different CETs and do not consider a specific PKPD model, the optimal drug concentration pair to achieve the half-maximal effect E maxAB 2 was investigated. In general, to apply optimization techniques, an objective function representing reasonable pharmacological evaluation criteria has to be chosen. Since one part of the CETs deal with one target and the others describe two targets, we either chose as objective function the Loewe Additivity or the Bliss Independence, both equipped with a combination index. Because every CET has to be treated separately, we selected the competitive, Bliss, Greco and the summation CET to introduce the optimization method and to present the optimal concentration pair for half-maximal effect. To simplify the calculations and to avoid distinction of cases, we investigated only Hill coefficients equal to one. Additionally, we focused our investigations to equal maximal single effects due to the properties of Eqs. (49)-(50). But we would like to emphasize that the objective functions based on Loewe or Bliss principles can be generalized for varying maximal single effects and Hill coefficients.
The Loewe, summation and IDR CETs can be straightforward extended for more than two drugs. An example of the Loewe CET for three drugs is shown in [47] . The competitive and Bliss CET have to be rederived from their basic principles. In the non-symmetric uncompetitive and non-competitive situation more knowledge about the desired interaction mechanisms is necessary.
Obviously, several other CETs exist to describe DDI. To obtain more flexibility, additional parameters were introduced, e.g. based on polynomials [13] , multi-parametric models with varying potencies [11] were developed, and approaches to cover wider ranges of combination behavior [12] were constructed. However, methods of such types were out of the scope of this manuscript.
In conclusion, the presented CETs are crucial components to describe a certain DDI mechanism in a PKPD model, and the presented and derived knowledge about CETs is essential to construct more mechanism-based PKPD models for DDI. 
Appendix 1: Drug receptor binding kinetics General derivation
From the conservation of receptors and complexes Eq. (11) we obtain the receptor representation
Rewriting the complexes Eqs. (8)- (10) with Eq. (51)
Pseudo steady-state analysis of Eqs. (52)- (54) for the complexes and substituting Eq. (54) into Eq. (52) then leads to
Dividing Eq. (55) by K DA and Eqs. (56)-(57) by K DB we obtain the matrix notation Eq. (12)
We apply Cramer's rule and obtain
Note that M 0 is strictly positive and M i , i ¼ 1; 2; 3 are non-negative for C A ; C B ! 0. The complexes then read
Inserting Eqs. (58)- (60) 
The complexes then read 
Agonistic-antagonist
For an antagonistic drug B we have e C B ð Þ ¼ 0 for C B ! 0 and therefore E maxB ¼ 0. Hence, we obtain with Eq. (18)
Appendix 3: Uncompetitive CET
Derivation
The determinants for Cramer's rule applied to Eq. (19) are
Substituting Eq. (65) in Eq. (26) gives Eq. (28). Equation (28) can be written with c A ¼ c B ¼ c as
Rearranging of Eq. (66) gives the Loewe CET Eq. (29).
Appendix 5: Bliss CET Diagonality
We have
Hence, the diagonality condition is satisfied with r ¼ 
and the diagonality condition is fulfilled with r ¼ a 4 .
Diagonality of the summation CET
For equal drugs we can compute
Thus, E Sum C A 2 ;
C A 2 À Á cannot be written in the form assumed in the diagonality condition. To see the last inequality please note that with
we have 
Appendix 7: IDR CETs Equivalent formulation for the inhibitory CET
To demonstrate the equivalence of Eq. (40) with Eqs. (41)- (42), we have to show
The denominator from Eq. (42) can be written as C A 2 À Á cannot be written in form of a single drug effect term. With similar calculations we obtain the same conclusion for I IDR .
Appendix 8: Relationships
To simplify the notation we set 
In the case of E maxA ¼ E maxB ¼ E max [ 0 and c A ; c B [ 0 we have
where g [ 0 indicates existence of the multiplicative term xy. In Eqs. (46)- (47) ; y ¼ C B EC 50B
: ð69Þ
Competitive CET
We assume E maxB ¼ E maxA ¼ E max [ 0. Using Eq. (18) by definition of the half maximal effect curve we have to solve
which is equivalent to
This leads to y ¼ 1 À x and the CET specific function for the half-maximal effect curve reads
The next step is to investigate the CI values on the halfmaximal effect curve which is due to Loewe Additivity Eq. (49) given by the objective function
with its specific u under the constraints x ! 0; u x ð Þ ! 0. In case of the competitive CET we obtain 
With Eq. (71) the objective function reads
and we calculate This leads to
; 0\ a j j 1:
we obtain
For a ¼ 0 we have h Greco x ð Þ ¼ x þ u Greco x ð Þ ¼ 1 which leads to CI Loewe ¼ 1.
Bliss CET
Using Eq. (33) we obtain
This leads to 
Rearranging with respect to y
We set with Eq. (50) 
